US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
about
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisTowards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.Breast cancer multigene testing trends and impact on chemotherapy use.21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
P2860
Q26861418-CCE6D374-86E7-4F25-9640-E53733DC85ABQ30252422-37FD14B7-B28E-4945-A9D8-9115C1FB2045Q34171119-096369BD-7E1A-43D2-80E1-FA6464817F50Q36424052-DE0F6F7F-5B42-46F4-94BD-888EF097DFE1Q37008507-78E6753D-5B99-4DCB-BF0D-018A40F7E201Q37083264-B6DFD190-108A-4C81-9DFC-2806803EC3B4Q37138266-2AFB0A44-39D3-46DE-A2EE-6C29F603A815Q37383276-D4BA2D39-68E5-40C0-8EA7-48026091C99AQ38024305-5D9BA542-5442-4136-8044-789F8EE14304Q38272730-82EE49F8-82DD-463D-AF83-F3AAB60FA9A1Q39187437-C22BF406-2410-4BDF-9524-F68194173BCCQ40124991-681BEB13-6438-4412-AF9E-A57D52928932Q40808798-E91BC253-5004-402D-9E1B-4C4E649C29EFQ48225891-DC2B60BE-DFE0-46EE-8232-098BAD48253FQ52585073-365E11E0-050A-49CF-A0CD-8BFD78C63772Q52586260-CDE2B87D-4BB3-4EDD-9EE0-9CCCCD366B72
P2860
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@ast
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@en
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@nl
type
label
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@ast
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@en
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@nl
prefLabel
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@ast
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@en
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@nl
P2093
P2860
P356
P1476
US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer.
@en
P2093
John Hornberger
Katie Krebs
Louis Hochheiser
Rebecca Chien
P2860
P304
P356
10.1200/JOP.2011.000303
P407
P433
P577
2011-05-01T00:00:00Z